• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Here’s How Much Money Pharma and Health-Care CEOs Made Last Year

By
Eric Boodman
Eric Boodman
and
STAT News
STAT News
Down Arrow Button Icon
By
Eric Boodman
Eric Boodman
and
STAT News
STAT News
Down Arrow Button Icon
May 26, 2016, 3:29 PM ET
Photograph by adventtr — Getty Images

This story originally appeared on STAT News.

Mirror, mirror, on the wall, who are the top-earning CEOs of them all?

A new report from the Associated Press and the research firm Equilar has some answers, and once again, many of the highest earners among execs running large companies are pharma and health care CEOs.

Consider Dr. Leonard S. Schleifer, the head of Regeneron Pharmaceuticals, based in Tarrytown, N.Y. His total compensation in 2015? More than $47 million. If he were working at New York state’s minimum wage — $9 an hour — it would have taken him well over 5 million hours to earn that much. That’s about 600 years of work without stopping to eat or sleep.

(Regeneron, by the way, just announced it’ll spend $100 million over the next decade to sponsor the nation’s largest high school science competition.)

Next on the list is Dr. Jeffrey M. Leiden, of Vertex Pharmaceuticals in Boston, at $28 million. That actually represents a pretty hefty pay cut for Leiden. He earned more than $36 million in 2014, which raised a few eyebrows given that the company had turned a profit just once in the previous quarter-century.

Related: A Little-Known Rule Could Force Startups to Divulge Financial Info

Larry J. Merlo, of CVS Health, clocks in at number 3 among health-care execs. His total compensation last year was just shy of $23 million — a 6 percent drop from the year before.

Here are the top 20 earners in the health care field, from the AP and Equilar, which analyzed CEO pay at hundreds of companies on the S&P 500:

  1. Leonard S. Schleifer, Regeneron Pharmaceuticals, $47,462,526
  2. Jeffrey M. Leiden, Vertex Pharmaceuticals, $28,099,826
  3. Larry J. Merlo, CVS Health, $22,855,374
  4. Robert J. Hugin, Celgene, $22,472,912
  5. Alex Gorsky, Johnson & Johnson, $21,128,866
  6. Michael F. Neidorff, Centene, $20,755,103
  7. Alan B. Miller, Universal Health Services, $20,427,309
  8. Kenneth C. Frazier, Merck & Co., $19,898,438
  9. Miles D. White, Abbott Laboratories, $19,410,704
  10. John C. Martin, Gilead Sciences, $18,755,952
  11. Richard A. Gonzalez, AbbVie, $18,534,310
  12. Heather Bresch, Mylan, $18,162,852
  13. David M. Cordani, Cigna, $17,307,672
  14. Mark T. Bertolini, Aetna, $17,260,806
  15. George A. Scangos, Biogen, $16,874,386
  16. Robert L. Parkinson, Baxter International, $16,648,750
  17. John C. Lechleiter, Eli Lilly & Co, $16,562,500
  18. Marc N. Casper, Thermo Fisher Scientific, $16,307,079
  19. Robert A. Bradway, Amgen, $16,097,714
  20. George Paz, Express Scripts Holding, $14,835,587

Total CEO compensation includes salary, bonus, stock and stock option awards, and other perks.

About the Authors
By Eric Boodman
See full bioRight Arrow Button Icon
By STAT News
See full bioRight Arrow Button Icon

Latest in

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in

LawElon Musk
Musk misled Twitter investors before 2022 buyout, jury says
By Isaiah Poritz, Jef Feeley and BloombergMarch 20, 2026
45 minutes ago
Economygeopolitics
Tariffs were already squeezing small businesses. Now the Iran conflict is pushing them to the brink as rising oil prices boost shipping costs
By Marco Quiroz-GutierrezMarch 20, 2026
1 hour ago
PoliticsIran
Trump says U.S. considers ‘winding down’ Iran military effort
By Jeff Mason, Courtney Subramanian and BloombergMarch 20, 2026
2 hours ago
bespectacled man scratches the back of his head during congressional hearing
CryptoCryptocurrency
Kalshi locks in $22 billion valuation, gaining slight edge over its rival Polymarket
By Carlos GarciaMarch 20, 2026
3 hours ago
Middle EastIran
It’s looking like Trump’s war created a private oil lane for China and other countries willing to play ball with Iran
By Jason MaMarch 20, 2026
4 hours ago
AsiaPepsiCo
Three Asias, three different playbooks: How PepsiCo’s Anne Tse views the world’s fastest-growing snack market
By Nicholas GordonMarch 20, 2026
4 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.